Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: dalfampridine, tedisamil, guanidine hydrochloride +3 | 1.00 |
| trials ClinicalTrials.gov | 8 Parkinson's trials, 1 stopped | 0.90 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly dopamine synapse | 1.00 |
Knock down and overexpress KCNG2 in a dopamine neuron, astrocyte and microglia tri-culture; measure evoked dopamine release and dopamine transporter uptake and dopamine neuron survival after α-synuclein fibril challenge.
- Cell type
- a dopamine neuron, astrocyte and microglia tri-culture
- Direction
- Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
- Molecular readout
- evoked dopamine release and dopamine transporter uptake
- Functional readout
- dopamine neuron survival after α-synuclein fibril challenge
- Rule-out
- If neither arm moves evoked dopamine release by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of KCNG2 in a tri-culture of iPSC dopamine neurons, astrocytes and microglia; n = 3 differentiations; readouts: evoked dopamine release and dopamine transporter uptake; dopamine neuron survival after α-synuclein fibril challenge. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- KCNG2 in dopamine neurons, braak-0.75 (p 0.019) → -0.12 (p 0.767)receipt 4771
Swarm cases
receipt 4771: KCNG2 in dopamine neurons, braak
- power
- full sample -0.45 (p 0.063, n 18), 95% CI -0.76 to +0.03. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.45 (p 0.063, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.47 (p 0.047, n 18). not the mix.
- skeptic
- leave-one-out range -0.59 to -0.38, sign flips 0; without severely affected donors -0.45 (p 0.063, n 18). robust.
- cell type
- strongest in OPCs: -0.61 (p 0.0067, n 18) vs -0.45 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for KCNG2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up KCNG2 · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.68 p 0.016 (needs p < 4.1e-4)
Receipts
loading the receipts